Corbus Pharmaceuticals Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
1.3%projected annual EPS growth
Analyst Coverage
10analysts covering
FY Revenue (est.)
$1.1Mnext fiscal year
FY EPS (est.)
-$5.43next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| CRB-701 Combination Data with Pembrolizumab | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly138.2MTarget: Sufficient to fund operations into 2028
CRB-701 Confirmed Objective Response Rate (ORR) in 2L OPSCC Annually42.9%Target: Maintain robust efficacy in registrational trials
CRB-913 Placebo-Adjusted Weight Loss at Day 14 (Phase 1a MAD) Annually0.0Target: Demonstrate competitive 12-week weight loss in Phase 1b CANYON-1
Watch Items
- CRB-913 Phase 1b CANYON-1 Topline DataTrigger: Topline 12-week weight loss and safety data releaseAction: Evaluate competitive positioning against GLP-1s and other oral obesity candidates; assess neuropsychiatric safety profile.
- CRB-701 TEMPO-1 Registrational Trial InitiationTrigger: First patient dosed in 2L OPSCC registrational studyAction: Monitor enrollment velocity and clinical site activation in the US and globally.
- CRB-701 Combination Data with PembrolizumabTrigger: Topline combination data releaseAction: Assess synergistic efficacy and safety/tolerability of the combination regimen.
Research as of 20 Jun 2026